Expert Insights

What are some goals in the management of polycythemia vera (PV)?

Read transcript Close transcript

In P vera, I think definitely you want hematocrit controlled below 45. Some people say it has to be controlled without phlebotomy. Some people would say it's ok if patients need some phlebotomy here and there. If they have leukocytosis, thrombocytosis, we want those controlled. If patients have no problems, if they are still negative, have reduction in the spleen, that's a generic form of response because that's what the ELN criteria define.

We know based on paper publications that a patient that has controlled hematocrit less than 45 had less events than patients that have their hematocrit between 45 and 50. So that's what most people aim for, so to have their hematocrit controlled, phlebotomies plus or minus cytoreductive therapy.

head shot of Dr Komrokji
Rami S Komrokji, MD Clinical Director of the Malignant Hematology Department Moffitt Cancer Center | Tampa, FL
Dr Rami Komrokji is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center and is a professor in medicine and oncologic sciences at the University of South Florida’s College of Medicine. Dr Komrokji has authored or co-authored more than 80 peer-reviewed manuscripts, 20 book chapters, and more than 200 abstracts on hematologic malignancies and is a peer reviewer for such medical journals as Blood, Journal of Clinical Oncology, and Leukemia. Dr Komrokji serves as a member on the MDS Panel of the National Comprehensive Cancer Network® (NCCN®).